NZ576590A - Tissue targeted antigenic activation of the immune response to treat cancers - Google Patents

Tissue targeted antigenic activation of the immune response to treat cancers

Info

Publication number
NZ576590A
NZ576590A NZ576590A NZ57659007A NZ576590A NZ 576590 A NZ576590 A NZ 576590A NZ 576590 A NZ576590 A NZ 576590A NZ 57659007 A NZ57659007 A NZ 57659007A NZ 576590 A NZ576590 A NZ 576590A
Authority
NZ
New Zealand
Prior art keywords
immune response
treat cancers
tissue targeted
antigenic activation
targeted antigenic
Prior art date
Application number
NZ576590A
Inventor
Harold David Gunn
Original Assignee
Qu Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/553,972 external-priority patent/US20070104733A1/en
Priority claimed from CA2571805A external-priority patent/CA2571805C/en
Application filed by Qu Biolog Inc filed Critical Qu Biolog Inc
Priority to NZ601232A priority Critical patent/NZ601232A/en
Publication of NZ576590A publication Critical patent/NZ576590A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided is a method for formulating an immunogenic composition for treating a melanoma cancer situated in a human patient's skin, comprising: producing an antigenic composition comprising a vaccinia virus; and, formulating the antigenic composition for administration as an immunogenic composition capable of eliciting an immune reaction to treat the melanoma cancer in the human patient. The medicament can be formulated for repeated subcutaneous or intradermal administration.
NZ576590A 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers NZ576590A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601232A NZ601232A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/553,972 US20070104733A1 (en) 2004-06-07 2006-10-27 Tissue targeted antigenic activation of the immune response to cancers
CA2571805A CA2571805C (en) 2006-10-27 2006-12-20 Tissue targeted antigenic activation of the immune response to cancers
PCT/CA2007/001915 WO2008049231A1 (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers

Publications (1)

Publication Number Publication Date
NZ576590A true NZ576590A (en) 2012-08-31

Family

ID=39324077

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ619899A NZ619899A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers
NZ576590A NZ576590A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers
NZ601232A NZ601232A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers
NZ715882A NZ715882A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ619899A NZ619899A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ601232A NZ601232A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers
NZ715882A NZ715882A (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers

Country Status (2)

Country Link
NZ (4) NZ619899A (en)
WO (1) WO2008049231A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
ES2645509T3 (en) * 2010-07-26 2017-12-05 Qu Biologics Inc Immunogenic anti-inflammatory compositions
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
KR20140033309A (en) * 2010-10-04 2014-03-18 브리티쉬 콜롬비아 캔써 에이전시 브랜치 Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
RU2020120075A (en) 2014-05-02 2020-07-03 Кью Байолоджикс Инк. ANTI-MICROBIAL IMMUNOMODULATION
CN109414461A (en) 2016-04-26 2019-03-01 曲生物制品公司 Therapeutically trigger the innate immune response in target tissue

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233076A1 (en) * 2000-02-01 2001-08-14 Michael A. O'donnell Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
US20060062807A1 (en) * 2001-12-11 2006-03-23 Marie-Anne Nahori Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
EP1765391B1 (en) * 2004-06-07 2013-03-06 Qu Biologics Inc Bacterial compositions for the treatment of cancer

Also Published As

Publication number Publication date
NZ715882A (en) 2017-07-28
NZ601232A (en) 2014-01-31
NZ619899A (en) 2016-08-26
WO2008049231A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
NZ576590A (en) Tissue targeted antigenic activation of the immune response to treat cancers
CN105797279B (en) Multifunctional far infrared negative ions magnet therapy silica gel beauty care device and mating cosmetics
Huynh et al. Tattoo and vaccination sites: Possible nest for opportunistic infections, tumors, and dysimmune reactions
CN205127149U (en) Subsides of stone needle acupuncture medicine
CN204016657U (en) Multi-functional arthritis nursing chair
CN204601109U (en) A kind of belt apparatus for acupuncture treatment
CN203303331U (en) Liquid medicine slow-release bionic moxibustion device
CN202569188U (en) Facial paralysis rehabilitation respirator
CN201267203Y (en) Adjustable magnetic medical health-care leather belt
CN208770694U (en) A kind of wear-type far infrared device
WO2004002412A3 (en) A method and composition to elicit an effective autologous antitumoral immune response in a patient
CN205127148U (en) Far infrared magnetotherapy medicine is applied ointment or plaster
CN2788834Y (en) Heating medicine therapeutical device
CN201782873U (en) Magnetic self-heating protector
CN204969585U (en) Far infrared analgesia shoulder pad function jacket
CN107485781A (en) A kind of artificial stereo eyebrow tattooing method
CN204484450U (en) A kind of fiery treatment Head And Face protects towel
CN201986722U (en) Ultraviolet light protection short pants
CN202876081U (en) Facial health preserving device for whitening and beauty
CN201939589U (en) Traditional Chinese medical bone-fracture treating device
CN201791272U (en) Local radiotherapy protecting device
CN209204014U (en) A kind of moxibustion with seed-sized moxa cone patch
CN203139097U (en) Moxa and ginger slice integral needle
WO2009054470A1 (en) Immune response inducer and use thereof
Kim et al. FCT 2-4 Measles, Mumps and Rubella (MMR) vaccine immunotherapy using two different products in wart treatment.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: QU BIOLOGICS INC, CA

Free format text: OLD OWNER(S): HAROLD DAVID GUNN

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 OCT 2014 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 OCT 2017 BY CPA GLOBAL

Effective date: 20140911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2018 BY CPA GLOBAL

Effective date: 20170929

LAPS Patent lapsed